TDF Long Term Study

ALternative TEnofovir Dosing in Adults With Moderate Renal Function Impairment

NCT01671982 ·Status: COMPLETED ·Phase: PHASE1

Tenofovir Renal Toxicity and Glomerular Filtration Rate (GFR) Validation

NCT01138241 ·Status: COMPLETED

Effect of Tenofovir DF on Bone Metabolism in Children

NCT00088309 ·Status: COMPLETED ·Phase: PHASE2

Second-line Therapy

NCT01788891 ·Status: COMPLETED

Bangkok Tenofovir Study, an HIV Pre-exposure Prophylaxis Trial, Bangkok, Thailand

NCT00119106 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Tenofovir Disoproxil Fumarate (TDF) in HIV-1 Patients Who Have Never Taken Anti-HIV Drugs

NCT00016588 ·Status: COMPLETED ·Phase: NA

Data Analysis for 04-C-0234 Tenofovir Disoproxil Fumarate Salvage Therapy in HIV-Infected Children and a Study of Its Effect on Bone Metabolism

NCT01361165 ·Status: COMPLETED

Open Label Extension (OLE) of the TDF2 Study, Botswana

NCT04318210 ·Status: COMPLETED ·Phase: NA

TDF Dose Adjustment VS. Switching to TAF in TDF-experienced CHB Patients With Renal Impairment

NCT04391608 ·Status: UNKNOWN ·Phase: PHASE4

Safety, Tolerance and Pharmacokinetics of Raltegravir-Containing Antiretroviral Therapy in Infants, Children Infected With HIV and TB

NCT01751568 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

NCT02121795 ·Status: COMPLETED ·Phase: PHASE3

Early Fast-Track Versus Standard Care for Persons With HIV Initiating TLD

NCT04311944 ·Status: UNKNOWN ·Phase: NA

Tenofovir Alafenamide Fumarate (TAF) Effect on Residual Intrathecal Immune Activation

NCT02771054 ·Status: COMPLETED ·Phase: PHASE4

A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment

NCT01709084 ·Status: COMPLETED ·Phase: PHASE3

Second-line Therapy Antiretroviral in Patients Who Failed Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) - Based Regimens

NCT00627055 ·Status: COMPLETED ·Phase: PHASE4

The Women TDF-FTC Benchmark Study

NCT05057858 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Switching TDF/FTC/EFV to TDF/FTC/RPV VS Continuing TDF/FTC/EFV in HIV Patients With Complete Virological Suppression

NCT03251690 ·Status: COMPLETED ·Phase: NA

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

NCT01967940 ·Status: COMPLETED ·Phase: PHASE3

Impact of Drug Therapy and Co-Morbidities on the Development of Renal Impairment in HIV-Infected Patients

NCT00551655 ·Status: COMPLETED

Pharmacokinetics of Intracellular TFV-DP and FTC-TP in HIV-infected Adolescents

NCT03800394 ·Status: COMPLETED

Genotyping Directed Salvage Therapy in Children Who Have Failed Dual NRTIs

NCT00477308 ·Status: COMPLETED ·Phase: NA

A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

NCT06337032 ·Status: RECRUITING ·Phase: PHASE4

The Women TAF-FTC Benchmark Study

NCT05140954 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Switching From TDF-based Antiretroviral Therapy Regimens to B/F/TAF in Virally Suppressed Adults With HIV-1 Infection

NCT05122754 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults

NCT01968551 ·Status: COMPLETED ·Phase: PHASE3